NCT01992588View on ClinicalTrials.gov

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

Faster-acting insulin aspart

"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."

DRUG

insulin aspart

"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY